Investment Q&A

Q: Retired, dividend-income investor. I am in the process of trimming my way out of Shaw (held in my TFSA) and looking at where to deploy the funds as they become available over time. I know WELL is not the same risk as SJR, but I am considering it.

However I really focus on asset allocation. I see WELL listed as Healthcare as well as Technology. Is it a hybrid? My tracking system has no problem with splitting it up into either or both sectors. As an example TC Energy, as a pipeline, is categorized as both a Utility as well as Energy. I believe it is a Utility, but because it seems to trade more like Energy stocks. I go 50-50.

I could do the same with WELL. What portion of their business is technology? Is any part of their business related to the Telecom sector? If I was forced to pick one sector, I'd go with Healthcare. Your thoughts?

Thanks....Steve

Q: Can I have your view on Berkeley Lights. Seeing strong revenue growth, cash on hand. Perhaps positive cash flow and profitability over the next 18-24mths..

Q: Good morning, would you be able to comment on NovaBay Pharmaceuticals, do you see it as a stock worth picking up, and if you do, at what entry point would you yourself feel comfortable going in? I have been waiting for it to go lower but it seems to have a good bit of strength in the .90-$1.00 range. I was hoping it would dip into the .70s but its not looking like that will happen again soon. Thank you!!

Q: Can you comment on DR's latest quarter. I am looking for an exit time but I thought it had enough momentum to reach $9. Now I am not so sure. Appreciate you comments.

Q: Haven’t seen a question since January. MDRA looks over sold and the stock has just issued a possible early technical buy signal using scholastics. More importantly this mRNA technology got another “shot in the arm” with the latest data indicting that they may work by STOPPING transmission not just mounting an immune response to decrease the course f the disease while you remain contagious. How well funded is MRNA. How is their free cash flow and their debt load. This technology keeps getting more and more exciting. Malaria, the common cold, HIV, etc!! And if is better maybe even influenza?
For the science geeks: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Aaron J Tande, MD, Benjamin D Pollock, PhD, MSPH, Nilay D Shah, PhD, Gianrico Farrugia, MD, Abinash Virk, MD, Melanie Swift, MD, MPH, Laura Breeher, MD, MPH, Matthew Binnicker, PhD, Elie F Berbari, MD Author Notes
Clinical Infectious Diseases, ciab229, https://doi.org/10.1093/cid/ciab229
Published: 10 March 2021

Q: How come PFE is muddling along despite having one of the top covid vaccines? How much of their revenue/growth does it make up - or are they just too massive to it to move the needle? What's PFE's growth outlook and valuation?

Q: So working in the finance industry, when it comes to business valuation, I know private health clinics get very low multiples. If Well is continues to consolidate in a space where now one else is and provides technological efficiencies. Even if they are just able to capture the majority of market share in Canada, could the potential upside be the sky?

Q: What would your thoughts be on the dialogue health ipo? How would they compare with well health?
Thanks

Q: Hi 5i,
Current shareholder of BMY for last 4 years and it simply has not done very much however pays small dividend of 3.2 %
I'm looking to sell and replace with something in same sector/space with better share price growth potential. Medium risk with 2- 3 year horizon. Dividend would be nice but not absolutely necessary.
Thx
Jim

Q: what can you tell me about this company.
i ask for 3 reasons;
cathie wood of ark keeps buying shares -what does she know that we do not.
also lloyd segals wife clarissa desjardins-he is ceo of repare sold her previous biotech for over 1 billion.
i know lightning never hits same spot twice.
also bristol myers seems to be heavily involved.
its cdn.-mtl based.
would you buy it.
dave

Q: DOC closed a bought deal today at 2.70 in the face of a market price which is much lower now but was a bit above the deal pricing when announced. I assume the brokers and/or underwriters will want to recover the value of their investment but I do not know how this sort of event generally proceeds. Can you clarify please, including the role and obligations of the parties and the likely outcome for the share price. Thanks

Q: Do you see a reason for the fall of ISRG other than it was in the "expensive" stock category?

Q: TSX Health Care Capped Index etc.. ...I cant find the symbols for these...also can pls explain the pros and cons of buying this type of investment ? why is it capped?is this a OK way of buying a specific sector of the market? how do they compare vs SPDR's..?

Q: Another acquisition by WELL (Intrahealth)....your comments?

Q: Hi 5I team,
I am a new member and enjoying your service and advise, so far.
I bought GUD (the dud) back in 2017 @ 9.88 when it was Peters top pick on BNN Market Call. It really hasn't preformed well since and appears to be getting worst. I have read all the questions and answers you've provided and still undecided as to how best to proceed. What is your advise going forward, "hang on" or bail out. Thanks
Homer

Q: I would like your comments on FLGT's Quarter and future guidance. It looked like a blowout to me but the market reaction seems quite muted at the time I am writing this. Guidance is also impressive, calling for revenues of $800m in 2021 a 90% yoy increase after an impressive 2020. FLGT has great margins of around 50%, so 4X next years sales tells us its trading around 8 times next year’s expected earnings….8X forward P/E is what you might expect on a sleepy, slow-growth stock. What am I missing, or is this simply being ignored on a bad market day? A Buy?

Q: I see ABCL is taking it on the chin today down 12% as I type this question. Since about January 1, 2021 I have been considering selling my NVTA and putting the money in ABCL but have done nothing to date. (Procrastination is sometimes the key to success)! NVTA weighting is 1.5%. 2 Questions...
Do you think ABCL has better long term prospects than NVTA and would you be interested in ABCL at +/- $31.50 USD? Or do you think I should use the basket approach and hold both?
Thanks,
Jim

Q: Whats going on with well When do they report and do you expect them to be profitable.

Q: Could you please comment on VHI's latest licensing deal.
Thanks as always.

VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce a multi-year large-scale licensing transaction of recently acquired subsidiary Intouch with Health’s (“Intouch”) Synopsis product with South Tees Hospitals NHS Foundation Trust (the “Trust” or “South Tees”).

This transaction is among VitalHub’s largest to-date, comprising a 5-year licensing contract for the Company’s proprietary, award-winning Synopsis platform. From initial questionnaire through to post-operative outcomes, Synopsis provides the necessary tools to enable hospitals to manage the entire pre-operative assessment process digitally – removing paper trails, increasing data security, and delivering significant organizational and economic benefits.

Q: hi I got in at20.00 Should I iake my lumps and get out or hang in there . Thanks in advance.. C,ifft